Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity

Summary

Two phase 3 randomised, placebo-controlled trials of weekly retatrutide in adults with painful knee osteoarthritis and obesity: TRIUMPH-4 (445 adults, 68 weeks) and TRIUMPH-1-OA (574 adults, 80 weeks). Retatrutide reduced WOMAC knee pain scores and body weight more than placebo. In TRIUMPH-4, mean body weight fell by 20.0% and 23.7% on the two retatrutide doses, against 4.6% with placebo; in TRIUMPH-1-OA it fell by 17.5% to 24.8%, against 4.3%. In a pooled analysis, 63.2% to 69.6% of participants on retatrutide at least halved their pain score at week 68, compared with 37.8% on placebo. Gastrointestinal events were the most common adverse events. The trials were not designed to assess joint structure. Published online on 8 November 2026 and presented at ACR Convergence 2026. Both trials were funded by Eli Lilly, which develops retatrutide. Retatrutide is investigational and not an approved medicine.

Peptides in this study

Retatrutide in the United Kingdom · Retatrutide in the United States · Retatrutide in Australia

All research on Retatrutide →

Related papers